// App-Quantinova.ai

: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma.

Researchers

Presenter

  • Thomas Powles

Principal Investigators

  • Peter H. O'Donnell

  • Christophe Massard

  • Hendrik-Tobias Arkenau

  • Terence W. Friedlander

  • Chris Hoimes

  • Jae-Lyun Lee

  • Michael Ong

  • Srikala S. Sridhar

  • Nicholas J. Vogelzang

  • Mayer N. Fishman

  • Jingsong Zhang

  • Sandy Srinivas

  • Jigar Parikh

  • Joyce Antal

  • Xiaoping Jin

  • Ashok Kumar Gupta

  • Noah M. Hahn

Medical Centers

  • Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

  • University of Chicago Comprehensive Cancer Center, Chicago, IL

  • Institut Gustave Roussy Cancer Centre, Villejuif, France

  • Sarah Cannon Research Institute, London, United Kingdom

  • University of California, San Francisco, San Francisco, CA

  • Case Western Reserve University-Nursing and Case Comprehensive Cancer Center, Cleveland, OH

  • Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

  • Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Comprehensive Cancer Centers of Nevada, Las Vegas, NV

  • Moffitt Cancer Center, Tampa, FL

  • Augusta University, Augusta, GA

  • MedImmune, Gaithersburg, MD

  • Johns Hopkins University, Baltimore, MD

Locations

  • United Kingdom

  • United States

  • France

  • Canada

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Durvalumab

  • SP263

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT01693562

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved